[PDF][PDF] Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations
…, KH Lee, R Shah, D Massey, V Zazulina… - Journal of clinical …, 2013 - static.vademecum.es
Purpose The LUX-Lung 3 study investigated the efficacy of chemotherapy compared with
afatinib, a selective, orally bioavailable ErbB family blocker that irreversibly blocks signaling …
afatinib, a selective, orally bioavailable ErbB family blocker that irreversibly blocks signaling …
Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from …
…, T Kato, D Massey, M Shahidi, V Zazulina… - The lancet …, 2015 - thelancet.com
Background We aimed to assess the effect of afatinib on overall survival of patients with
EGFR mutation-positive lung adenocarcinoma through an analysis of data from two open-label, …
EGFR mutation-positive lung adenocarcinoma through an analysis of data from two open-label, …
Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised …
…, M Shahidi, M Kim, D Massey, V Zazulina… - The Lancet …, 2016 - thelancet.com
Background The irreversible ErbB family blocker afatinib and the reversible EGFR tyrosine
kinase inhibitor gefitinib are approved for first-line treatment of EGFR mutation-positive non-…
kinase inhibitor gefitinib are approved for first-line treatment of EGFR mutation-positive non-…
Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2 …
Background Most patients with non-small-cell lung cancer tumours that have EGFR mutations
have deletion mutations in exon 19 or the Leu858Arg point mutation in exon 21, or both (ie…
have deletion mutations in exon 19 or the Leu858Arg point mutation in exon 21, or both (ie…
Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study
Background No targeted therapies are available for KRAS-mutant non-small-cell lung cancer
(NSCLC). Selumetinib is an inhibitor of MEK1/MEK2, downstream of KRAS, with preclinical …
(NSCLC). Selumetinib is an inhibitor of MEK1/MEK2, downstream of KRAS, with preclinical …
Symptom control and quality of life in LUX-Lung 3: a phase III study of afatinib or cisplatin/pemetrexed in patients with advanced lung adenocarcinoma with EGFR …
…, KJ O'Byrne, TSK Mok, V Zazulina… - Journal of Clinical …, 2013 - ascopubs.org
Purpose Patient-reported symptoms and health-related quality of life (QoL) benefits were
investigated in a randomized, phase III trial of afatinib or cisplatin/pemetrexed. Patients and …
investigated in a randomized, phase III trial of afatinib or cisplatin/pemetrexed. Patients and …
[HTML][HTML] First-line afatinib versus chemotherapy in patients with non–small cell lung cancer and common epidermal growth factor receptor gene mutations and brain …
…, S Popat, LV Sequist, D Massey, V Zazulina… - Journal of Thoracic …, 2016 - Elsevier
Introduction Metastatic spread to the brain is common in patients with non–small cell lung
cancer (NSCLC), but these patients are generally excluded from prospective clinical trials. The …
cancer (NSCLC), but these patients are generally excluded from prospective clinical trials. The …
Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma
…, P Hersey, M Middleton, M Cantarini, V Zazulina… - Clinical Cancer …, 2012 - AACR
Purpose: To compare the efficacy and tolerability of the mitogen-activated protein (MAP)/extracellular
signal-regulated (ERK) kinase (MEK) 1/2 inhibitor selumetinib versus …
signal-regulated (ERK) kinase (MEK) 1/2 inhibitor selumetinib versus …
LUX-Lung 6: A randomized, open-label, phase III study of afatinib (A) versus gemcitabine/cisplatin (GC) as first-line treatment for Asian patients (pts) with EGFR …
…, JH Shi, KY Lee, D Massey, Y Shi, J Chen, V Zazulina… - 2013 - ascopubs.org
8016 Background: A is an oral, irreversible, ErbB Family Blocker, blocking signaling from
EGFR (ErbB1), HER2 (ErbB2) and ErbB4. A was superior to first-line pemetrexed/cisplatin in a …
EGFR (ErbB1), HER2 (ErbB2) and ErbB4. A was superior to first-line pemetrexed/cisplatin in a …
Overall survival (OS) in patients (pts) with advanced non-small cell lung cancer (NSCLC) harboring common (Del19/L858R) epidermal growth factor receptor …
…, V Hirsh, SL Geater, C Zhou, D Massey, V Zazulina… - 2014 - ascopubs.org
8004^ Background: Afatinib (A) is an oral, irreversible ErbB family blocker of EGFR, HER2,
ErbB3 and ErbB4 signalling. LL3 compared A with cisplatin/pemetrexed in 345 pts recruited …
ErbB3 and ErbB4 signalling. LL3 compared A with cisplatin/pemetrexed in 345 pts recruited …